Brief: Paratek Pharmaceuticals Announces Commercial Availability Of U.S.-Produced Nuzyra (Omadacycline) Tablets
31/10/2022 12:17
Oct 31 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS INC - ANNOUNCES COMMERCIAL
AVAILABILITY
OF U.S.-PRODUCED NUZYRA (OMADACYCLINE) TABLETS
Source text for Eikon: ID:nGNX8ssKfr
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million